| 產(chǎn)品名稱 | Cediranib - AZD 2171 |
| 產(chǎn)品貨號 | Axon 1461 CAS [288383-20-0] MF C25H27FN4O3MW 450.51 Purity: 99% Soluble in DMSO Description highly potent and orally available tyrosine kinase inhibitor (TKI), targeting VEGF receptor; thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth References Certificates Categories Extra info SR Wedge et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005, 65 (10), 4389–400.? ? G Goss et al. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine. Eur. J. Cancer 2008, 45, 782.? ? P Nikolinakos & JV Heymach. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J. Thorac. Oncol. 2008, 3 (6 Suppl 2): S131–4.? ? CA Heckman et al.?The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 2008, 68(12), 4754-4762. Certificate of Analysis Material Safety Data Sheet Angiogenesis Cell Signaling & Oncology VEGFR RTK class IV; EC 2.7.10.1 VEGFR tyrosine kinase inhibitor Chemical name 4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-yl-propoxy)-quinazoline Parent CAS No. [288383-20-0] Order Size Unit Price Stock 5 mg €70.00 In Stock |
| 產(chǎn)品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
Cediranib - AZD 2171Axon 1461 CAS [288383-20-0] MF C25H27FN4O3
Description
highly potent and orally available tyrosine kinase inhibitor (TKI), targeting VEGF receptor; thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth
VEGFR tyrosine kinase inhibitor
Chemical name4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-yl-propoxy)-quinazoline Parent CAS No.[288383-20-0] |
| 產(chǎn)品資料 |
